PriceTargets.com logo

NASDAQ:ASLN - ASLAN Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.33
  • Forecasted Upside: 1,431.64 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.41 As of 05/24/2022 01:00 AM ET
▼ -0.02 (-4.61%)

This chart shows the closing price for ASLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ASLAN Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASLN

Analyst Price Target is $6.33
▲ +1,431.64% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ASLAN Pharmaceuticals in the last 3 months. The average price target is $6.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,431.64% upside from the last price of $0.41.

This chart shows the closing price for ASLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in ASLAN Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022HC WainwrightReiterated RatingBuy$8.00Low
5/23/2022Piper SandlerLower Price TargetOverweight$8.00 ➝ $3.00High
12/7/2021HC WainwrightReiterated RatingBuyHigh
10/5/2021BTIG ResearchReiterated RatingHoldMedium
9/28/2021HC WainwrightReiterated RatingBuy$8.00High
8/9/2021HC WainwrightReiterated RatingBuy$8.00Low
7/15/2021HC WainwrightReiterated RatingBuy$8.00Low
7/9/2021Jefferies Financial GroupInitiated CoverageBuy$8.00High
5/12/2021HC WainwrightReiterated RatingBuy$8.00Low
5/11/2021Piper SandlerLower Price Target$9.00 ➝ $8.00High
3/17/2021HC WainwrightBoost Price TargetBuy$5.00 ➝ $8.00High
1/12/2021HC WainwrightReiterated RatingBuyLow
7/14/2020HC WainwrightReiterated RatingBuy$5.00High
5/12/2020HC WainwrightReiterated RatingBuy$5.00High
3/19/2020HC WainwrightReiterated RatingBuy$5.00Low
3/19/2020Piper SandlerLower Price Target$8.00 ➝ $6.00Medium
12/10/2019HC WainwrightReiterated RatingPositive ➝ Buy$2.00 ➝ $5.00Low
12/2/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$8.00High
11/25/2019HC WainwrightReiterated RatingBuy$2.00Medium
11/14/2019HC WainwrightLower Price TargetBuy$9.00 ➝ $2.00High
11/11/2019Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
11/11/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
9/30/2019Piper Jaffray CompaniesSet Price TargetBuy$7.00Low
6/5/2019HC WainwrightSet Price TargetBuy$9.00Low
1/24/2019HC WainwrightReiterated RatingBuyHigh
1/14/2019HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $8.50High
12/7/2018HC WainwrightReiterated RatingBuy$12.00Medium
8/21/2018HC WainwrightReiterated RatingBuy$12.00High
7/3/2018HC WainwrightReiterated RatingBuy$12.00Medium
5/30/2018SVB LeerinkInitiated CoverageMarket Perform$7.00High
5/30/2018BTIG ResearchInitiated CoverageBuy$16.00High
5/30/2018HC WainwrightInitiated CoverageBuy$12.00High
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweightHigh
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

ASLAN Pharmaceuticals logo
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Read More

Today's Range

Now: $0.41
Low: $0.40
High: $0.45

50 Day Range

MA: $0.70
Low: $0.41
High: $0.92

52 Week Range

Now: $0.41
Low: $0.40
High: $3.87

Volume

150,351 shs

Average Volume

184,205 shs

Market Capitalization

$28.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.33

Frequently Asked Questions

What sell-side analysts currently cover shares of ASLAN Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on ASLAN Pharmaceuticals in the last twelve months: BTIG Research, HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ASLN.

What is the current price target for ASLAN Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for ASLAN Pharmaceuticals in the last year. Their average twelve-month price target is $6.33, suggesting a possible upside of 1,431.6%.
View the latest price targets for ASLN.

What is the current consensus analyst rating for ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASLN will outperform the market and that investors should add to their positions of ASLAN Pharmaceuticals.
View the latest ratings for ASLN.

How do I contact ASLAN Pharmaceuticals' investor relations team?

ASLAN Pharmaceuticals' physical mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company's listed phone number is 65-6222-4235 and its investor relations email address is [email protected] The official website for ASLAN Pharmaceuticals is www.aslanpharma.com. Learn More about contacing ASLAN Pharmaceuticals investor relations.